BIOMAT Database Logo BIOMAT Database Logo

Adjuvant treatment in stage I and II malignant melanoma: a randomized trial between chemoimmunotherapy and immunotherapy. 1991

T Castel, and J Estapé, and N Viñolas, and J M Mascaró, and J Castro, and A Vilalta, and R Gratacós, and M Daniels, and J Palou, and J J Grau
Cátedra de Dermatología, Hospital Clínic, Barcelona, España.

A randomized trial comparing chemoimmunotherapy (bacillus Calmette-Guérin + chemotherapy) and immunotherapy (bacillus Calmette-Guérin alone) was carried out in high-risk stage I and II malignant melanoma patients. Eight-two evaluable patients were included. The follow-up median duration was 11 years. Recurrent melanoma developed in 28 patients (34%). The overall survival rate was 76% at 5 years and 65% at 10 years. There were no statistical differences in survival probability or disease-free survival (DFS) probability between the two treatment groups. Survival and DFS were also analyzed in relation to various prognostic factors. Statistically significant differences were only seen in a subset of 33 patients with lower limb malignant melanoma, the prognosis being better for the chemoimmunotherapy group in this location. Because of the small number of patients in each group, a week positive effect of either of these two treatments cannot be ruled out. Chemoimmunotherapy only seems to improve the prognosis of stage I or II malignant melanoma of the legs.

UI MeSH Term Description Entries
D008297 Male Males
D008545 Melanoma A malignant neoplasm derived from cells that are capable of forming melanin, which may occur in the skin of any part of the body, in the eye, or, rarely, in the mucous membranes of the genitalia, anus, oral cavity, or other sites. It occurs mostly in adults and may originate de novo or from a pigmented nevus or malignant lentigo. Melanomas frequently metastasize widely, and the regional lymph nodes, liver, lungs, and brain are likely to be involved. The incidence of malignant skin melanomas is rising rapidly in all parts of the world. (Stedman, 25th ed; from Rook et al., Textbook of Dermatology, 4th ed, p2445) Malignant Melanoma,Malignant Melanomas,Melanoma, Malignant,Melanomas,Melanomas, Malignant
D008875 Middle Aged An adult aged 45 - 64 years. Middle Age
D003131 Combined Modality Therapy The treatment of a disease or condition by several different means simultaneously or sequentially. Chemoimmunotherapy, RADIOIMMUNOTHERAPY, chemoradiotherapy, cryochemotherapy, and SALVAGE THERAPY are seen most frequently, but their combinations with each other and surgery are also used. Multimodal Treatment,Therapy, Combined Modality,Combined Modality Therapies,Modality Therapies, Combined,Modality Therapy, Combined,Multimodal Treatments,Therapies, Combined Modality,Treatment, Multimodal,Treatments, Multimodal
D003606 Dacarbazine An antineoplastic agent. It has significant activity against melanomas. (from Martindale, The Extra Pharmacopoeia, 31st ed, p564) DTIC,5-(3,3-Dimethyl-1-triazeno)imidazole-4-carboxamide,Biocarbazine,DIC,DTIC-Dome,Decarbazine,Deticene,Dimethyl Imidazole Carboxamide,Dimethyl Triazeno Imidazole Carboxamide,ICDT,NSC-45388,Carboxamide, Dimethyl Imidazole,DTIC Dome,DTICDome,Imidazole Carboxamide, Dimethyl,NSC 45388,NSC45388
D005260 Female Females
D005500 Follow-Up Studies Studies in which individuals or populations are followed to assess the outcome of exposures, procedures, or effects of a characteristic, e.g., occurrence of disease. Followup Studies,Follow Up Studies,Follow-Up Study,Followup Study,Studies, Follow-Up,Studies, Followup,Study, Follow-Up,Study, Followup
D006801 Humans Members of the species Homo sapiens. Homo sapiens,Man (Taxonomy),Human,Man, Modern,Modern Man
D006918 Hydroxyurea An antineoplastic agent that inhibits DNA synthesis through the inhibition of ribonucleoside diphosphate reductase. Hydroxycarbamid,Hydrea,Oncocarbide
D000328 Adult A person having attained full growth or maturity. Adults are of 19 through 44 years of age. For a person between 19 and 24 years of age, YOUNG ADULT is available. Adults

Related Publications

T Castel, and J Estapé, and N Viñolas, and J M Mascaró, and J Castro, and A Vilalta, and R Gratacós, and M Daniels, and J Palou, and J J Grau
Adjuvant chemoimmunotherapy stage I/II malignant melanoma.
March 1982, Journal of surgical oncology,
T Castel, and J Estapé, and N Viñolas, and J M Mascaró, and J Castro, and A Vilalta, and R Gratacós, and M Daniels, and J Palou, and J J Grau
Adjuvant BCG immunotherapy for stage I and II malignant melanoma.
June 1983, Canadian Medical Association journal,
T Castel, and J Estapé, and N Viñolas, and J M Mascaró, and J Castro, and A Vilalta, and R Gratacós, and M Daniels, and J Palou, and J J Grau
Trial 6: randomized study of prolonged chemotherapy, immunotherapy, and chemoimmunotherapy as an adjuvant to surgery for stage I and II melanoma: a progress report.
January 1982, Recent results in cancer research. Fortschritte der Krebsforschung. Progres dans les recherches sur le cancer,
T Castel, and J Estapé, and N Viñolas, and J M Mascaró, and J Castro, and A Vilalta, and R Gratacós, and M Daniels, and J Palou, and J J Grau
A randomized trial of adjuvant chemotherapy and immunotherapy in Stage I and Stage II cutaneous melanoma. An interim report.
February 1985, Cancer,
T Castel, and J Estapé, and N Viñolas, and J M Mascaró, and J Castro, and A Vilalta, and R Gratacós, and M Daniels, and J Palou, and J J Grau
Adjuvant immunotherapy with BCG in stage II malignant melanoma.
June 1983, Journal of surgical oncology,
T Castel, and J Estapé, and N Viñolas, and J M Mascaró, and J Castro, and A Vilalta, and R Gratacós, and M Daniels, and J Palou, and J J Grau
Experience with BCG adjuvant immunotherapy in stage II malignant melanoma.
January 1977, Tumori,
T Castel, and J Estapé, and N Viñolas, and J M Mascaró, and J Castro, and A Vilalta, and R Gratacós, and M Daniels, and J Palou, and J J Grau
Experience with BCG adjuvant immunotherapy in stage II malignant melanoma.
January 1977, Developments in biological standardization,
T Castel, and J Estapé, and N Viñolas, and J M Mascaró, and J Castro, and A Vilalta, and R Gratacós, and M Daniels, and J Palou, and J J Grau
Malignant melanoma (stage 1): a clinical trial of adjuvant BCG immunotherapy.
January 1978, Recent results in cancer research. Fortschritte der Krebsforschung. Progres dans les recherches sur le cancer,
T Castel, and J Estapé, and N Viñolas, and J M Mascaró, and J Castro, and A Vilalta, and R Gratacós, and M Daniels, and J Palou, and J J Grau
Adjuvant therapy in malignant melanoma: a trial of immunotherapy. chemotherapy, and combined treatment.
January 1978, Recent results in cancer research. Fortschritte der Krebsforschung. Progres dans les recherches sur le cancer,
T Castel, and J Estapé, and N Viñolas, and J M Mascaró, and J Castro, and A Vilalta, and R Gratacós, and M Daniels, and J Palou, and J J Grau
Chemoimmunotherapy (DTIC and Corynebacterium parvum) as adjuvant treatment in malignant melanoma.
January 1979, Cancer treatment reports,
Copied contents to your clipboard!